Vertex (VRTX) Form 144 Notice — 266 Shares Scheduled for Sale
Rhea-AI Filing Summary
Vertex Pharmaceuticals (VRTX) Form 144 notice: An individual filer intends to sell 266 shares of Vertex common stock through Fidelity Brokerage Services on the NASDAQ, with an aggregate market value of $102,859.54 and approximately 256,390,651 shares outstanding. The securities were acquired on May 1, 2024 via restricted stock vesting from the issuer and were paid as compensation on the same date. The approximate sale date is listed as August 27, 2025. The filer reports no other sales in the past three months and affirms no undisclosed material adverse information.
Positive
- None.
Negative
- None.
Insights
TL;DR: Small insider sale in absolute terms; unlikely to be material to VRTX but noteworthy as a scheduled Rule 144 disposition.
The filing documents a planned off-exchange sale under Rule 144 of 266 vested restricted shares, valued at about $102.9k, executed through Fidelity and scheduled for August 27, 2025. Given the issuer's outstanding share count (~256.4 million), this represents an immaterial dilution percentage and is routine for insiders disposing of vested compensation. No prior sales in the past three months were reported, and the filer certifies lack of undisclosed material information. Impact on market valuation is likely negligible.
TL;DR: The Form 144 appears compliant: acquisition, nature, payment, broker, and intended sale date are disclosed.
The notice provides the required Rule 144 elements: acquisition date (05/01/2024), nature of acquisition (restricted stock vesting), consideration (compensation), broker details, number of shares, aggregate market value, and planned sale date. The filer signed the standard representation regarding material nonpublic information and reported no sales in the prior three months. From a compliance perspective, the filing meets disclosure expectations for a standard Rule 144 sale.